CN105980372B - 官能化的苯并吡喃化合物及其用途 - Google Patents

官能化的苯并吡喃化合物及其用途 Download PDF

Info

Publication number
CN105980372B
CN105980372B CN201580002687.5A CN201580002687A CN105980372B CN 105980372 B CN105980372 B CN 105980372B CN 201580002687 A CN201580002687 A CN 201580002687A CN 105980372 B CN105980372 B CN 105980372B
Authority
CN
China
Prior art keywords
cancer
compound
compounds
formula
300mhz
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201580002687.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN105980372A (zh
Inventor
A·西顿
D·布朗
G·凯利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vivetho Co Ltd Publicly Listed
Original Assignee
Novogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novogen Ltd filed Critical Novogen Ltd
Priority to CN201810378034.2A priority Critical patent/CN108484559A/zh
Publication of CN105980372A publication Critical patent/CN105980372A/zh
Application granted granted Critical
Publication of CN105980372B publication Critical patent/CN105980372B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/06—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2
    • C07D311/08—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring
    • C07D311/16—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 2 not hydrogenated in the hetero ring substituted in position 7
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing aromatic rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN201580002687.5A 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途 Active CN105980372B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810378034.2A CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461937368P 2014-02-07 2014-02-07
US61/937,368 2014-02-07
US201461987323P 2014-05-01 2014-05-01
US61/987,323 2014-05-01
PCT/AU2015/050040 WO2015117202A1 (en) 2014-02-07 2015-02-05 Functionalised benzopyran compounds and use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN201810378034.2A Division CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Publications (2)

Publication Number Publication Date
CN105980372A CN105980372A (zh) 2016-09-28
CN105980372B true CN105980372B (zh) 2018-05-08

Family

ID=53777071

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201580002687.5A Active CN105980372B (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途
CN201810378034.2A Pending CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201810378034.2A Pending CN108484559A (zh) 2014-02-07 2015-02-05 官能化的苯并吡喃化合物及其用途

Country Status (24)

Country Link
US (2) US9701655B2 (https=)
EP (1) EP2953938B1 (https=)
JP (1) JP6570042B2 (https=)
KR (1) KR102395543B1 (https=)
CN (2) CN105980372B (https=)
AU (1) AU2015213484B2 (https=)
BR (1) BR112016018099B8 (https=)
CA (1) CA2936012C (https=)
CL (1) CL2016001937A1 (https=)
DK (1) DK2953938T3 (https=)
ES (1) ES2643407T3 (https=)
IL (1) IL241515B (https=)
LT (1) LT2953938T (https=)
MX (1) MX368063B (https=)
MY (1) MY195739A (https=)
NZ (1) NZ711603A (https=)
PH (1) PH12016501422B1 (https=)
PL (1) PL2953938T3 (https=)
PT (1) PT2953938T (https=)
RU (1) RU2676766C2 (https=)
SA (1) SA516371583B1 (https=)
SG (2) SG11201604490SA (https=)
SI (1) SI2953938T1 (https=)
WO (1) WO2015117202A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX368063B (es) * 2014-02-07 2019-09-18 Novogen ltd Compuestos de benzopirano funcionalizados y uso de los mismos.
CN116139125A (zh) 2015-02-02 2023-05-23 梅制药公司 联合治疗
US10265294B2 (en) * 2016-03-31 2019-04-23 Yale University Compositions and methods for treating epithelial cancer
CA3058503A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Isoflavonoid composition with improved pharmacokinetics
CA3058492A1 (en) * 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
CN109700798A (zh) * 2017-03-01 2019-05-03 浙江大学 苯并吡喃黄酮结构类型雄激素受体拮抗剂及其应用
EP4125870A1 (en) 2020-03-30 2023-02-08 Noxopharm Limited Methods for the treatment of inflammation associated with infection
AU2021286662A1 (en) * 2020-06-11 2023-02-09 Mei Pharma, Inc. Combination therapies
WO2023235929A1 (en) * 2022-06-08 2023-12-14 Noxopharm Limited Functionalised benzopyran compounds and uses thereof
CN118005594B (zh) * 2023-05-24 2024-10-29 内蒙古大学 3-羟基苯并二氢吡喃衍生物的合成及其抗肿瘤活性

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101094844A (zh) * 2004-09-21 2007-12-26 诺沃根研究控股有限公司 苯并二氢吡喃衍生物，药物及其在治疗中的应用
CN101123958A (zh) * 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3340276A (en) 1964-04-01 1967-09-05 Ciba Geigy Corp 3, 4-diphenyl-chromans
US3822287A (en) 1969-04-17 1974-07-02 Rexall Drug Chemical Process for preparation of substituted 3,4-(diphenyl)chromans
US4447622A (en) 1981-09-22 1984-05-08 Council Of Scientific And Industrial Research Rafi Marg Preparation of l- and d-isomers of dl-3,4-trans-2,2-disubstituted-3,4-diarylchromans and derivatives thereof
BE891562A (fr) 1981-12-21 1982-04-16 Council Scient Ind Res Isomeres 1 et d de d1-3, 4-trans-3, 4-diarylchromanes 2, 2-disubstitues et leurs derives, leur preparation et leur utilisation
US5451603A (en) 1993-03-11 1995-09-19 Zymogenetics, Inc. 3,4-diarylchromans for treatment of dermatitis
US5280040A (en) 1993-03-11 1994-01-18 Zymogenetics, Inc. Methods for reducing bone loss using centchroman derivatives
HUP9702244A3 (en) 1995-01-13 1999-12-28 Novo Nordisk As Use of 3,4-diphenyl chromans for manufacture of a pharmaceutical composition for treatment or prophylaxis of gynaecological disorders
EP0804189A1 (en) 1995-01-13 1997-11-05 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of hyperlipoproteinaemia, hypertriglyceridaemia, hyperlipidaemia or hypercholesterolaemia or arteriosclerosis or for anticoagulative treatment
AU702407B2 (en) 1995-01-13 1999-02-18 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment of prophylaxis of idiopathic or physiologic gynaecomastia
CA2208856A1 (en) 1995-01-20 1996-07-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of cerebral degenerative disorders
CZ211897A3 (en) 1995-01-20 1997-12-17 Novo Nordisk As Use of 3,4-diphenylchromans for preparing pharmaceutical preparations used for dilation of vessels
TW448046B (en) 1995-01-20 2001-08-01 Novo Nordisk As Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of obesity
US5883118A (en) 1996-01-11 1999-03-16 Nova Nordisk A/S Prostatic carcinoma
WO1997025035A1 (en) 1996-01-11 1997-07-17 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for the treatment or prophylaxis of menopausal symptoms
US5747059A (en) 1996-01-11 1998-05-05 Novo Nordisk A/S Atrophy of skin/mucous membrane
CN1207038A (zh) 1996-01-11 1999-02-03 诺沃挪第克公司 3,4－二苯基苯并二氢吡喃在生产预防或治疗绝经症状的药物组合物中的应用
US5726202A (en) 1996-01-11 1998-03-10 Novo Nordisk A/S Benign prostatic hypertrophy
US5756539A (en) 1996-07-11 1998-05-26 Novo Nordis A/S 3, 4-diphenyl chromans for inhibiting one or more psychiatric disorders
US5780502A (en) 1996-07-12 1998-07-14 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical composition for inhibiting one or more symptoms of premenstrual syndrome
US5919817A (en) 1996-10-28 1999-07-06 Novo Nordisk A/S Cis-3, 4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
US6043269A (en) 1996-10-28 2000-03-28 Novo Nordisk A/S cis-3,4-chroman derivatives useful in the prevention or treatment of estrogen related diseases or syndromes
ZA979642B (en) 1996-10-28 1998-04-28 Novo Nordisk As Heterocyclic compounds, compositions and uses.
US5925771A (en) 1996-10-28 1999-07-20 Novo Nordisk A/S Process for the preparation of (-)-3,4-trans-diarylchromans
JP2001502704A (ja) 1996-10-28 2001-02-27 ノボ ノルディスク アクティーゼルスカブ エストロゲン関連疾患又は症候群の予防又は処置において有用な新規ｃｉｓ―３，４―クロマン誘導体の新規の（―）―鏡像異性体
AU5550398A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor inhibiting senescence-associated motor impairment
AU5550298A (en) 1997-01-29 1998-08-25 Novo Nordisk A/S Use of 3,4-diphenyl chromans for the manufacture of a pharmaceutical compositionfor increasing libido in post-menopausal women
US6184005B1 (en) 1998-04-28 2001-02-06 Novo Nordisk A/S Enzymatic resolvation for obtaining a (−)-3,4-trans-diarylchroman
DK1115398T3 (da) * 1998-09-23 2010-08-16 Res Dev Foundation Tocopheroler, tocotrienoler, andre chroman- og sidekædederivater og anvendelser deraf
WO2001007031A1 (en) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Benzene derivatives and immunopotentiating compositions or drug-sensitivity restoring agents containing the same
US7226945B2 (en) 2000-10-13 2007-06-05 Astrazeneca Ab Estrogen receptor-β ligands
JP4256679B2 (ja) 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法
US20050119301A1 (en) 2001-03-16 2005-06-02 Alan Husband Treatment of restenosis
JP2005524630A (ja) 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
US20040167165A1 (en) 2003-01-16 2004-08-26 Geetha Shankar Methods of treating conditions associated with an Edg-7 receptor
EP1634958B1 (en) 2003-06-04 2009-02-18 Mitsubishi Gas Chemical Company, Inc. Method for producing optically active chroman-carboxylate
CA2581316C (en) 2004-09-21 2013-09-10 Novogen Research Pty Ltd Substituted chroman derivatives, medicaments and use in therapy
JP4913056B2 (ja) * 2004-09-21 2012-04-11 マーシャル エドワーズ，インコーポレーテッド 置換クロマン誘導体、医薬品、および治療における使用
EP2436680B1 (en) * 2004-09-21 2016-05-18 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
US7528267B2 (en) 2005-08-01 2009-05-05 Girindus America, Inc. Method for enantioselective hydrogenation of chromenes
US20090221564A1 (en) 2006-02-21 2009-09-03 Trigen Limited Heterocyclic Compounds and Their Use in the Treatment of Cardiovascular Disease
AU2007314141A1 (en) 2006-10-30 2008-05-08 Novogen Research Pty Ltd Prevention and reversal of chemotherapy-induced peripheral neuropathy
CN101210012B (zh) 2006-12-31 2011-09-14 南华大学 新的含烟酸异黄酮酯衍生物及其制造方法和用途
WO2010022467A1 (en) 2008-08-29 2010-03-04 Novogen Research Pty Ltd Immunomodulating activities
US20100130598A1 (en) 2008-10-22 2010-05-27 Novogen Research Pty Ltd. Methods for inducing programmed cell death
AU2008230055A1 (en) 2008-10-22 2010-05-06 Novogen Research Pty Ltd Methods for Inducing Programmed Cell Death
US8952054B2 (en) 2010-03-15 2015-02-10 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of MUC1 and methods of identifying the same
US9139592B2 (en) 2010-06-14 2015-09-22 Trt Pharma Inc. Modulators of Nrf2 and uses thereof
CN102153535A (zh) 2011-03-04 2011-08-17 中国海洋大学 一种抗肿瘤多药耐药抑制剂苯并吡喃-3-醇酯化衍生物及其制备方法和应用
US20150018566A1 (en) * 2011-08-25 2015-01-15 The Provost, Fellows, Foundation Scholars, & the Other Members of Board, of The College of the Holy Tubulin binding agents
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
CN103408528B (zh) 2013-08-13 2015-04-29 浙江大学 一种色满化合物及其制备方法和应用
CN103450142B (zh) 2013-09-04 2015-03-25 浙江大学 一种色满化合物及其提取方法和应用
CN103585145A (zh) 2013-11-28 2014-02-19 常州科立信医疗器械有限公司 Artoxanthochromane在治疗前列腺癌药物中的应用
CN103690525A (zh) 2013-12-02 2014-04-02 常州科立信医疗器械有限公司 Artoxanthochromane在治疗舌癌药物中的应用
CN103638008B (zh) 2013-12-02 2015-09-16 刘艳娇 Artoxanthochromane在治疗皮肤癌药物中的应用
CN103705503A (zh) 2013-12-04 2014-04-09 常州科立信医疗器械有限公司 Artoxanthochromane在治疗乳腺癌药物中的应用
MX368063B (es) * 2014-02-07 2019-09-18 Novogen ltd Compuestos de benzopirano funcionalizados y uso de los mismos.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101123958A (zh) * 2003-11-19 2008-02-13 诺沃根研究股份有限公司 联合放射疗法与化学疗法的组合物和方法
CN101094844A (zh) * 2004-09-21 2007-12-26 诺沃根研究控股有限公司 苯并二氢吡喃衍生物，药物及其在治疗中的应用
WO2012061409A1 (en) * 2010-11-01 2012-05-10 Marshall Edwards, Inc. Isoflavonoid compounds and methods for the treatment of cancer
US20120251630A1 (en) * 2011-03-29 2012-10-04 Marshall Edwards, Inc. Remission therapy of cancer with isoflavonoids

Also Published As

Publication number Publication date
JP6570042B2 (ja) 2019-09-04
CA2936012C (en) 2023-03-07
RU2016133731A3 (https=) 2018-08-08
US10370349B2 (en) 2019-08-06
US20180141925A1 (en) 2018-05-24
JP2017507175A (ja) 2017-03-16
US9701655B2 (en) 2017-07-11
RU2676766C2 (ru) 2019-01-11
KR20160110427A (ko) 2016-09-21
AU2015213484B2 (en) 2015-11-05
SA516371583B1 (ar) 2019-04-18
BR112016018099B1 (pt) 2022-10-11
PL2953938T3 (pl) 2017-12-29
DK2953938T3 (en) 2017-10-02
ES2643407T3 (es) 2017-11-22
WO2015117202A1 (en) 2015-08-13
KR102395543B1 (ko) 2022-05-09
SI2953938T1 (en) 2018-01-31
EP2953938A1 (en) 2015-12-16
CN108484559A (zh) 2018-09-04
BR112016018099B8 (pt) 2023-01-17
SG11201604490SA (en) 2016-07-28
CA2936012A1 (en) 2015-08-13
IL241515A0 (en) 2015-11-30
EP2953938B1 (en) 2017-08-02
NZ711603A (en) 2017-05-26
MX2016010137A (es) 2017-02-15
MY195739A (en) 2023-02-08
PH12016501422A1 (en) 2016-08-31
CL2016001937A1 (es) 2017-01-20
RU2016133731A (ru) 2018-03-12
IL241515B (en) 2019-06-30
CN105980372A (zh) 2016-09-28
AU2015213484A1 (en) 2015-09-17
PT2953938T (pt) 2017-10-09
PH12016501422B1 (en) 2022-02-16
US20160340329A1 (en) 2016-11-24
SG11201506988TA (en) 2015-10-29
HK1218914A1 (en) 2017-03-17
EP2953938A4 (en) 2016-08-10
BR112016018099A2 (pt) 2017-08-08
LT2953938T (lt) 2017-10-10
MX368063B (es) 2019-09-18

Similar Documents

Publication Publication Date Title
CN105980372B (zh) 官能化的苯并吡喃化合物及其用途
JP6666494B2 (ja) がんの処置のための医薬の組合せ
PL199781B1 (pl) Nowe związki pochodne chinoliny, zastosowanie związków pochodnych chinoliny, zawierające je kompozycje farmaceutyczne i sposób ich wytwarzania
JP7181565B2 (ja) Ｙａｐ－ｔｅａｄ結合を阻害する化合物、およびそれを有効成分として含有する癌の予防または治療用医薬組成物
JP2016530285A (ja) 癌の撮像及び治療のためのハロゲン化化合物、及びその使用方法
JP2021508318A (ja) チューブリン阻害剤
TW201138764A (en) Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents
KR20210027382A (ko) 접히지 않은 단백질 반응의 활성화제
WO2012022780A1 (en) 18-beta-glycyrrhetinic acid derivatives with anti-tumor activity
CA2868120C (en) Kinase inhibitors for the treatment of cancer
CN103130632B (zh) 1-取代苯亚甲基-2-萘酮类衍生物及制备方法和用途
HK1263249A1 (en) Functionalised benzopyran compounds and use thereof
CN114026098B (zh) 苯并吡喃基化合物、方法及其用途
HK1218914B (en) Functionalised benzopyran compounds and use thereof
TWI723030B (zh) 二氫異丹蔘酮ｉ於治療癌症之用途
AU2015201006A1 (en) Benzopyran compounds and use thereof
KR20100004681A (ko) ｐ21의 발현을 증가시키는 활성을 갖는 화합물5,4'-디메톡시플라본의 항암제로서의 용도

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: New South Wales Australia

Applicant after: NOVOGEN LTD.

Address before: New South Wales Australia

Applicant before: NOVOGEN LTD.

GR01 Patent grant
GR01 Patent grant
TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20250908

Address after: Solna, Sweden

Patentee after: Vivetho Co., Ltd. (Publicly Listed)

Country or region after: Sweden

Address before: New South Wales Australia

Patentee before: NOVOGEN LTD.

Country or region before: Australia